Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-05T14:28:47.692Z Has data issue: false hasContentIssue false

47 - Introduction to Venture Capital in Alzheimer’s Disease Drug Development

from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development

Published online by Cambridge University Press:  03 March 2022

Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

Venture capital can play a role in bridging the gap between laboratory-based research and therapies developed by pharmaceutical companies for Alzheimer’s disease (AD). The Dementia Discovery Fund (DDF), was formed to provide funding and expertise to support companies developing novel treatments for dementia. Combining a focus on dementia with the rigour of for-profit venture capital investing greatly improves the odds of developing an effective therapeutic. Investment decisions are based on credible, proven science with the potential to deliver a drug, supported by excellent management teams. The DDF supports companies both financially and strategically drawing on the vast experience of its team of venture investors and scientific experts. Building syndicates with other investors de-risks individual investments, also providing the company with access to more capital and range of expertise. With a recent increase in the amount of available risk capital, coupled with a better understanding of the pathophysiology of AD and the use of precision medicine approaches, venture capital can have a greater impact on the discovery and development of a life-changing drug for patients with AD.

Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
, pp. 524 - 532
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cummings, JL, Morstorf, T, Zhong, K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014; 6: 37.Google Scholar
Sabbagh, JJ, Kinney, JW, Cummings, J. Animal systems in the development of treatments for Alzheimer’s disease: challenges, methods, and implications. Neurobiol Aging 2013; 34: 169–83.Google Scholar
Windisch, M. We can treat Alzheimer’s disease successfully in mice but not in men: failure in translation? A perspective. Neurodegen Dis 2014; 13: 147–50.Google Scholar
Lo, AW, Ho, C, Cummings, J, Kosik, KS. Parallel discovery of Alzheimer’s therapeutics. Sci Transl Med 2014; 6: 241cm245.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×